New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
04:55 EDTLIFE, LIFE, LIFE, SI, SI, SI, BIOL, BIOL, BIOL, IVC, IVC, IVC, VAR, VAR, VAR, ARAY, ARAY, ARAY, CPHD, CPHD, CPHD, MASI, MASI, MASI, HRC, HRC, HRC, RHHBY, RHHBY, RHHBY, MCK, MCK, MCKWorldwide Business Research to host a conference
Field Service Medical Conference is being held in San Diego on February 19-21.
News For LIFE;RHHBY;HRC;MASI;CPHD;ARAY;VAR;IVC;BIOL;SI;MCK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 19, 2014
08:51 EDTRHHBYBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
06:12 EDTRHHBYRoche says breast cancer study did not meet PFS superiority endpoint
Subscribe for More Information
06:10 EDTRHHBYRoche to discontinue Phase III study of Alzheimer's disease drug
Roche announced the decision to discontinue SCarlet RoAD, a phase III study of investigational anti-amyloid medicine gantenerumab in prodromal Alzheimer’s disease, based on results of a pre-planned futility analysis and recommendation by the independent Data Monitoring Committee. No new safety signals for gantenerumab were observed in this analysis and the overall safety profile was similar to that seen in the phase I trial, Roche said. Data from the SCarlet RoAD study will be shared with the medical community after full review and analysis, it added. "We are disappointed with these study results because people with early stage Alzheimer's need new medicines that delay disease progression,” said Sandra Horning, M.D., Chief Medical Officer at Roche. "This is the first Phase III trial to evaluate a potential disease-modifying medicine in this early prodromal stage of Alzheimer’s disease. We remain committed to investigating new medicines for this devastating illness."
05:36 EDTRHHBYImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
05:33 EDTRHHBYGenentech provides update on Phase III MARIANNE
Subscribe for More Information
December 18, 2014
12:46 EDTRHHBYRoche acquires privately held Dutalys for $133.75M up front
Roche announced that it has agreed to acquire Dutalys GmbH, a privately held biotechnology company based in Vienna, Austria. Dutalys specializes in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMab technology, Roche said. Under the terms of the agreement, Roche will make an upfront cash payment of $133.75M to shareholders and make additional contingent payments of up to $355M based on the achievement of certain predetermined milestones.
10:01 EDTCPHDOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:07 EDTCPHDCepheid upgraded to Buy from Neutral at BofA/Merrill
December 17, 2014
12:12 EDTVARVarian Medical announces intention to acquire MeVis Medical Solutions AG
Subscribe for More Information
December 16, 2014
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
11:42 EDTMCKMcKesson management to meet with FBR Capital
Field trip to company headquarters to be held in San Francisco on December 18 hosted by FBR Capital.
10:00 EDTARAYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:19 EDTARAYAccuray initiated with a Neutral at SunTrust
Target $7.
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 9, 2014
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:44 EDTRHHBYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 8, 2014
11:30 EDTMCKLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
07:26 EDTCPHDLeerink to hold a tour
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use